PetVivo Holdings, Inc. (OTCQB: PETVD) – (Symbol to revert back to PETV after 20 business days from December 29th) could become to be known as one of the great value plays in the biotech sectors.
As an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals, PetVivo Holdings, Inc. is leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.
There are only a handful of “majors” in this space.
Zoetis, Inc. (NYSE: ZTS), being the largest discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Zoetis is trading at 46 times (TTM) earnings with a market cap of $76.7 billion.
PetIQ, Inc. (NASDAQ: PETQ) operates as a pet medication and wellness company through two segments, Products and Services. The company offers prescription pet medications, including products for arthritis, thyroid, and diabetes and pain treatments, as well as heartworm preventatives, antibiotics, and other specialty medications; and over-the-counter medications and supplies, such as flea and tick control products in various forms comprising spot on treatments, chewables, and collars among providing other health and wellness products.
PetIQ trades at over a $1 billion valuation while losing (TTM) $3.24 per share.
IDEXX Laboratories, Inc. (NASDAQ: IDXX) together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary and livestock markets worldwide. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community.
IDEXX Laboratories trades at 85 times (TTM) earnings with a market cap of a $41.3 billion.
PetVivo, Inc. (OTCQB: PETV), is the producer of “Kush”, which is a veterinarian-administered intraarticular injection for the treatment of osteoarthritis and other lameness issues in dogs and horses is intended to provide a lubricious cushion between the bones to reinforce cartilage. KUSH is scheduled for expanded commercial sales and the development of its proprietary mucoadhesive active agent delivery products.
Kush is made from all-natural materials; collagen elastin and heparin, lasts for 12 months or longer and can be repeated each year. Kush is expected to launch in Q1 2021, with sales in the $4.8 billion dog and horse therapeutics market. Petvivo (OTCQB: PETV) currently has 16 products in its pipeline, and a portfolio of 19 patents that protect them.
PetVivo may or may not be on an acquisition path, as there is really no way to know for sure. That beings said however, PetVivo (OTCQB: PETVD, PETV), is on an aggressive growth / valuation path of their own. The Company published a press release on December 29, 2020 announcing a reverse stock split in efforts to improve the company’s capital structure related to listing requirements for a planned future listing of the company’s common stock on the Nasdaq Capital Market.
On November 23, 2020, PetVivo Holdings (OTCQB: PETV) filed an 8-K where the Company adopted and approved an amended and restated “Charter of the Audit Committee”, “Charter of the Compensation Committee” and a “Nominating and Corporate Governance Committee Charter?” All of which are required by NASDAQ.
PetVivo has set up the committee’s, conducted the reverse split, and now seems to have all the makings of a NASDAQ stock. See page 11 of the “Nasdaq Official Listing Guide of June 2020”.
PetVivo announced in August that the United States Patent and Trademark Office (USPTO) has allowed an important patent related to the Company’s proprietary biomaterial, which the company utilizes to produce its proprietary products.
The broad scope of the issued claims in this patent, entitled “Protein Biomaterials and Biocoacervates and Methods of Making and Using Thereof,” provides tremendous proprietary protection for a broad range of proprietary products, including the product Kush, a medical device treatment for animal osteoarthritis.
Any of the majors listed above could benefit from PetVivo’s proprietary assets. Either path however, being acquired by a major, organic growth with an up list to a major exchange, or one of a dozen intermediaries, PetVivo Holdings, Inc. (OTCQB: PETVD, PETV), is on a track for growth, and in hindsight could be looked back upon as one of the great undervalued pure biotech plays.
Through its evolution, EmergingGrowth.com found a niche in identifying companies that can be overlooked by the markets. We look for strong management, innovation, strategy, execution, and the overall potential for long- term growth. Aside from being a trusted resource for the Emerging Growth info-seekers, we are well known for discovering undervalued companies and bringing them to the attention of the investment community. Through our parent Company, we also have the ability to facilitate road shows to present your products and services to the most influential investment banks in the space.